Given its central role in immune signaling, MyD88 is a potential therapeutic target. Inhibitors of MyD88 signaling are being explored as treatments for autoimmune diseases and inflammatory conditions. Additionally, targeting MyD88 pathways may also have potential in cancer therapy, particularly in tumors where chronic inflammation plays a role in cancer progression.
